Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

  • Published on 14/11/2023
  •  Reading time: 4 min.

Paolo Sportoletti 1, Luca Laurenti 2, Annalisa Chiarenza 3, Gianluca Gaidano 4, Elisa Albi 5, Francesca Romana Mauro 6, Livio Trentin 7, Daniele Vallisa 8, Fabrizio Pane 9, Antonio Cuneo 10, Francesco Albano 11, Giulia Zamprogna 12, Marta Coscia 13, Alessandro Gozzetti 14, Gianluigi Reda 15, Morena Caira 16, Paola Finsinger 16, Giuliana Gualberti 16, Emilia Iannella 16, Simona Malgieri 16, Stefano Molica 17

1 Institute of Hematology and Center for Hemato‐Oncology Research University of Perugia and Santa Maria della Misericordia Hospital Perugia Italy
2 Hematology Institute Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
3 Division of Hematology Ferrarotto Hospital Catania Italy
4 Division of Haematology Department of Translational Medicine Università del Piemonte Orientale and Azienda Ospedaliero‐Universitaria Maggiore della Carità Novara Italy
5 Strategic Research Programme in CLL Division of Experimental Oncology IRCCS Ospedale San Raffaele and Università Vita‐Salute San Raffaele Milan Italy
6 Hematology Department of Translational and Precision Medicine 'Sapienza' University Rome Italy
7 Hematology Section Department of Medicine Azienda Ospedale Università Padova Padova Italy
8 Hematology Unit Department of Oncology and Hematology Guglielmo da Saliceto Hospital Piacenza Italy
9 Department of Clinical Medicine and Surgery Federico II University Naples Italy
10 Hematology Section Department of Medical Sciences Azienda Ospedaliera‐Universitaria Arcispedale S. Anna University of Ferrara Ferrara Italy
11 Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe‐J) Hematology and Stem Cell Transplantation Unit University of Bari "Aldo Moro" Bari Italy
12 Department of Hematology Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy
13 Department of Molecular Biotechnology and Health Sciences University of Torino and Division of Hematology A.O.U. Città della Salute e della Scienza di Torino Torino Italy
14 Hematology Department of Medicine, Surgery and Neurosciences University of Siena Siena Italy
15 Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore University of Milan Milan Italy
16 AbbVie S.r.l. Campoverde Latina Italy
17 Department of Hematology‐Oncology Azienda Ospedaliera Pugliese‐Ciaccio Catanzaro Italy


Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatment line, and socio‐demographic characteristics in a cross sectional, observational study conducted at 16 Italian hematology centers. Study visits occurred between February and July 2020; 401 adult patients with CLL (201 Watch and Wait...


To continue reading this article in Full-Text...

* Registration is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Hematology

Receive our newsletter to stay up to date with the latest news in Hematology

More articles

From peer-reviewed journals in Hematology